Corticosteroid News and Research

RSS

Corticosteroids are any steroid hormones made in the adrenal cortex (the outer part of the adrenal gland). They are also made in the laboratory. Corticosteroids have many different effects in the body, and are used to treat many different conditions. They may be used as hormone replacement, to suppress the immune system, and to treat some side effects of cancer and its treatment. Corticosteroids are also used to treat certain lymphomas and lymphoid leukemias.

Health Canada to review Cipher’s self-adhesive medicated plaster, Beteflam Patch

Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Beteflam Patch (previously called the Betesil® Patch) has been accepted for review by Health Canada.

13 Feb 2015

First patients treated with Orthocell's tendon repair therapy in Hong Kong

Regenerative medicine company Orthocell Limited has announced it has expanded its presence in Asia with the first patients treated with its world-leading tendon repair therapy in Hong Kong.

10 Feb 2015

Steroid use associated with five-fold increase of blood clots in IBD patients

Compared with biologic therapy, corticosteroid (steroid) use is associated with a nearly five-fold increase of venous thromboembolism in inflammatory bowel disease (IBD) patients, according to a new study1 in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

30 Jan 2015

FDA grants orphan drug status to NBI-77860 for treatment of congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has been granted orphan drug status by the United States Food and Drug Administration (FDA) for the treatment of congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the United States.

16 Jan 2015

EC grants orphan drug designation to TxCell's Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis.

18 Dec 2014

Persistent eosinophilia common in COPD

More than one-third of patients with chronic obstructive pulmonary disease have persistent eosinophilia, researchers report in the European Respiratory Journal.

27 Nov 2014

Low asthma medication adherence predictors identified in adolescents

Inhaled corticosteroid adherence among adolescents with asthma is low and is associated with a lack of knowledge about treatment and patients’ perceptions about their medicines, show findings of a study published in the Journal of Asthma.

25 Nov 2014

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in patients with asthma

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.

11 Nov 2014

Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours after surgery).

7 Oct 2014

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids.

30 Sep 2014

Alimera announces FDA approval of ILUVIEN for treatment of diabetic macular edema

Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration has approved ILUVIEN for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).

27 Sep 2014

LABA-ICS combination therapy better than LABAs alone for COPD

Among older adults with chronic obstructive pulmonary disease (COPD), particularly those with asthma, newly prescribed long-acting beta-agonists (LABAs) and inhaled corticosteroid combination therapy, compared with newly prescribed LABAs alone, was associated with a lower risk of death or COPD hospitalization, according to a study in the September 17 issue of JAMA.

17 Sep 2014

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

Boehringer Ingelheim today presented new data from the company's Phase III trial program (UniTinA-asthma®) evaluating tiotropium in asthma, including the first study assessing the efficacy and safety of tiotropium in adolescent patients with symptomatic asthma.

9 Sep 2014

Asthma medication adherence strategies identified

Keeping asthma medication in the bathroom and incorporating its use into daily routines are strategies associated with good medication adherence in older adults with asthma, US research shows.

3 Sep 2014

Clinical study shows long-term effectiveness of Orthocell’s Ortho-ATI™ for treatment resistant tennis elbow

Regenerative medicine company Orthocell Limited has today released results from a long-term clinical study into its Ortho-ATI™ treatment for tennis elbow that provides evidence of the durability and long term success of this treatment.

25 Aug 2014

FDA approves GlaxoSmithKline’s Arnuity Ellipta for treatment of asthma

GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older. Arnuity is not indicated for relief of acute bronchospasm.

21 Aug 2014

Physiological variables best predict adult asthma phenotypes

Physiological variables are more consistent predictors of adult asthma phenotypes than inflammatory biomarkers, an international team of researchers suggests.

13 Aug 2014

Only 52% of women receive low-cost treatment to prevent babies death

A major international study of more than 303 000 births in 29 low-income and middle-income countries has found that only half (52%) of women who are eligible to receive a simple, effective, low-cost treatment to prevent death and disability in their newborn babies are getting it.

13 Aug 2014

Study provides care coaches with useful ideas to help older patients improve asthma medication rituals

Storing it in the bathroom and making it part of a daily routine may be helpful advice that doctors can give their older asthmatic patients who struggle to remember to take their daily prescribed medication.

6 Aug 2014

Artesunate drug can be used to control asthma, finds NUS study

Asthmatic patients may soon have a more effective way to control the condition, thanks to a new pharmacological discovery by researchers from the National University of Singapore.

3 Aug 2014